Efficiency in R&D is calculated more often than not through the return on investments made on therapeutic candidates, when they reach their commercialization stage and are able to earn revenue for the company who has developed it.
The most basic way to understand the candidate’s journey through pre-clinical and clinical development is by assessing the same parameters of other candidates already in the space. To help pharmaceutical companies assess the current scenario of a particular indication, or a particular Mechanism of Action, or a particular Active Pharmaceutical Ingredient, or a particular Drug candidate, etc. DelveInsight’s insight-packed reports provide clarity on uncertainties and challenge blind spots to provide timely intelligence to the company.